|
Q4 FY2025
As of Mar 31, 2025
|
Q3 FY2025
As of Dec 31, 2024
|
Q2 FY2025
As of Sep 30, 2024
|
Q1 FY2025
As of Jun 30, 2024
|
Q4 FY2024
As of Mar 31, 2024
|
Q3 FY2024
As of Dec 31, 2023
|
Q2 FY2024
As of Sep 30, 2023
|
Q1 FY2024
As of Jun 30, 2023
|
Q4 FY2023
As of Mar 31, 2023
|
Q3 FY2023
As of Dec 31, 2022
|
Q2 FY2023
As of Sep 30, 2022
|
Q1 FY2023
As of Jun 30, 2022
|
Q4 FY2022
As of Mar 31, 2022
|
Q3 FY2022
As of Dec 31, 2021
|
Q2 FY2022
As of Sep 30, 2021
|
Q1 FY2022
As of Jun 30, 2021
|
Q4 FY2021
As of Mar 31, 2021
|
Q3 FY2021
As of Dec 31, 2020
|
Q2 FY2021
As of Sep 30, 2020
|
Q1 FY2021
As of Jun 30, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Mortgage-backed securities, at fair value(1) | ||||||||||||||||||||
| Securities, at fair value(1) | ||||||||||||||||||||
| Other investments, at fair value | ||||||||||||||||||||
| Due from brokers | ||||||||||||||||||||
| Financial derivatives–assets, at fair value | ||||||||||||||||||||
| Reverse repurchase agreements | ||||||||||||||||||||
| Receivable for securities sold | ||||||||||||||||||||
| Interest receivable | ||||||||||||||||||||
| Interest and principal receivable | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| Payable for securities purchased | ||||||||||||||||||||
| Due to brokers | ||||||||||||||||||||
| Financial derivatives–liabilities, at fair value | ||||||||||||||||||||
| U.S. Treasury securities sold short, at fair value | ||||||||||||||||||||
| Dividend payable | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Management fee payable to affiliate | ||||||||||||||||||||
| Interest payable | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Preferred shares, par value $0.01 per share, 100,000,000 shares authorized; (0, 1,000, and 0 shares issued and outstanding, respectively) | ||||||||||||||||||||
| Common shares, par value $0.01 per share, 500,000,000 shares authorized; (37,559,195, 29,651,553, and 18,601,464 shares issued and outstanding, respectively) | ||||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Shareholders' Equity | ||||||||||||||||||||
| Total Liabilities and Shareholders' Equity |
Loading...
